Navigation Links
Reducing the Cost and Increasing the Precision of Future Medicines
Date:2/10/2015

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2015 /PRNewswire/ -- While the merits of the proposed Precision Medicine Initiative are hotly debated, Cloud Pharmaceuticals, a drug development start-up in Durham, North Carolina, has been quietly making the promise of precision medicine more attainable.

Cloud Pharmaceuticals is breaking new ground in the field of "in silico" drug discovery – that is, performed on a computer or via computer modeling and simulation of molecules.

"The successful treatment of diseases depends on effective medicine, consisting of molecules that bind to specific biological targets," says Shahar Keinan, CSO of Cloud Pharmaceuticals. "Our technology, called Inverse Design, computationally designs small molecules and peptides that inhibit the activity of protein targets, which are produced by the genes responsible for certain pathologies."

This design process takes place much more quickly and effectively than traditional methods. Qualified drug candidates can therefore be identified and advanced to the next stages of development more rapidly to reduce the cost, increase efficacy, reduce toxicity, and enable precision medicine by providing more than one drug per target.  

Overcoming the obstacles of in silico

How can Cloud Pharmaceuticals' novel technology deliver on the promise of faster, more effective drug design? Past in silico methods, such as "docking," have inconsistent results due to inaccurate prediction of activity. Inverse Design overcomes these challenges by combining three different technologies, as Cloud Pharmaceuticals CEO Ed Addison explains.

"There are an estimated 1065 stable molecules with a molecular weight below 850 available for exploration. Researching this space by direct enumeration and evaluation is too slow and too expensive. We use patented search algorithms to locate the best molecules in that vast space," Addison says. "Our method combines high-performance cloud computing, quantum mechanics/molecular mechanics (QM/MM), and molecular property simulation. This approach enables us to calculate accurate binding affinities in a fraction of the time and choose only molecules that could make a useful drug. Plus we're able to identify novel drug candidates that exhibit low probability of toxic side effects and high probability of success."

Targeting proteins at a molecular level

The efficiency and speed of developing novel drug candidates with Inverse Design is that it enables the creation of a virtual "hit list" of molecules that bind to protein targets. More than one drug can be developed per indication that can later be matched to people with certain genetic markers. This targeting enables adaptive drug trials so the best drugs can be chosen for a given patient, changing the drug development paradigm to be more suited to precision medicine.

"Very often, the same protein will mutate and cause different types of illness or disease," Keinan adds. "Therefore, targeting proteins at a molecular level helps to identify more effective treatment protocols."

Bringing precision medicine within reach

It's clear that the worldwide pharmaceutical industry is in need of new treatment options that target smaller market segments, are developed faster, and have novel IP, greater drug safety, efficacy, and affordability. Cloud Pharmaceuticals is poised to help.

"If the vision of precision medicine and eventually personalized medicine is to happen, it is important that new breakthroughs and better applications emerge for computational drug discovery," Addison says. "Accurately calculating binding affinities between a protein and a small molecule is critical to rationally designing new drugs – and that's exactly what we do."

Available Topic Experts: For information on the listed experts, click appropriate link.
Shahar Keinanhttp://www.profnetconnect.com/skeinan
Ed Addison - http://www.profnetconnect.com/edaddison


'/>"/>
SOURCE Cloud Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Chronic Kidney Disease: Reducing Risks of Progression-- Prismic Pharmaceuticals Secures Exclusive Licensing Rights
2. Wesley Medical Center Nominated for Best of 2013 Respiratory Care: Improves Patient Safety By Reducing Opioid-Related Adverse Events to Zero
3. Novartiss Serelaxin Has the Potential to Fulfill the Most Pertinent Unmet Needs in Acute Heart Failure by Reducing the Rate of Patient Mortality and the Rate of Worsening Renal Function
4. Acme Posture Partner Positioning System Provides Excellent Posture Support and Spinal Alignment While Reducing Pain and Enhancing Overall Comfort
5. Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth
6. Increasing Demand from End-user Applications Boosts Asia-Pacific Antimicrobial Coatings Market, Finds Frost & Sullivan
7. Increasing Public Health Awareness Intensifies Global Uptake of Autoimmune Disease Diagnostics
8. Increasing Affluence and Legislative Reforms are Transforming Polands Pharmaceutical Market, Which Holds Strategic Importance for Multinational Companies
9. The Systemic Lupus Erythematosus Market Will Grow Dramatically Over the Next Decade, Increasing from Approximately $900 Million in 2012 to $4 Billion in 2022
10. First Financial Expands into Canada to Meet Increasing Demand for its Leasing Solutions
11. Pressure Relief Devices Market to 2019 - Increasing Focus on Pressure Ulcer Prevention and Quality of Care to Drive Growth: Industry Analysis, Size, Share, Growth, Trends and Forecast Now Available at MarketResearchReports.biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2019)... ... December 02, 2019 , ... Smile Brands Inc., one ... the United States, today announced the grand opening of another affiliated Bright ... will enjoy convenient hours, a comfortable office and full-service care at the new ...
(Date:12/2/2019)... ... 2019 , ... Strong public health departments engaged in effective ... Striving to fulfill their crucial mission, more and more health departments are placing ... Health Accreditation Board (PHAB). Today, PHAB announced it has awarded initial five-year accreditation ...
(Date:11/30/2019)... ... November 28, 2019 , ... Craig Wallentine, ... elected chairman of the board of trustees of the International Safety Equipment ... President & CEO, Ergodyne , was elected vice chairman. , Nate Kogler, ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... 06, 2019 , ... C&A Industries , a national ... The Omaha-based company has been named by Training magazine to the Training ... development programs worldwide. Rankings of the 125 leading companies will be announced on ...
(Date:12/6/2019)... , ... December 06, 2019 , ... Allegheny Health Network ... Dr. Gyure, who joined AHN from WVU Medicine in May 2018, previously served as ... has served as interim chair since October and is also part of the pathology ...
(Date:12/6/2019)... ... 06, 2019 , ... TIME For Kids (TFK) revealed the first-ever ... innovative, and fun destinations that are tailored to the interests of kids. The list ... To assemble the list, TIME for Kids gathered nominations from its network of ...
(Date:12/5/2019)... , ... December 05, 2019 , ... ... M&A: Risks and Rewards of Building Platforms— on Thursday, December 12, 2019, at ... for large, multi-specialty medical groups. Middle-market PE firms are scrambling to assemble regional ...
(Date:12/4/2019)... ... , ... A November 12 article on NBC Connecticut reported on ... The article highlighted the life-changing or life-ending consequences of some E-scooter accidents, from a ... fatality after an incident with a vehicle. Los Angeles-based personal injury law firm Legal ...
Breaking Medicine News(10 mins):